Published in:
01-07-2016 | Preeclampsia (VD Garovic, Section Editor)
Aspirin vs Heparin for the Prevention of Preeclampsia
Authors:
Vasiliki Katsi, Theoni Kanellopoulou, Thomas Makris, Petros Nihoyannopoulos, Efrosyni Nomikou, Dimitrios Tousoulis
Published in:
Current Hypertension Reports
|
Issue 7/2016
Login to get access
Abstract
Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide. Preeclampsia can be resolved by delivery, and most of the proposed preventive treatment approaches are based on processes involved in placental development in early pregnancy. Yet, none of these has been established in clinical practice. Low-dose aspirin is the most promising candidate, nevertheless; while some individual randomized controlled trials showed minimal or no statistically significant benefit, recent metanalyses showed that early initiation before 16 weeks of gestation is associated with prevention of early-onset preeclampsia and reduction in prevalence of perinatal death or morbidity of pregnant women. Heparin could be an alternative antithrombotic and anti-inflammatory median to prevent preeclampsia either alone or in combination with aspirin; however, results are conflicting concerning efficacy.